Richard E. Champlin

TL;DR: In de novo CML‐AP, early response at 3 and 6 months is a strong determinant of long‐term outcome, and the impact of various degrees of molecular and cytogenetic response at early time points is determined.

TL;DR: A 17‐year‐old girl developed severe aplastic anaemia following an episode of infectious mononucleosis and underwent mobilization with filgrastim and subsequent leukapheresis for blood stem cell collection, which led to durable trilineage haematological recovery still ongoing at 16 months after her second transplant.

TL;DR: It is suggested that haploidentical grafts might be a preferred donor source for second AHSCT as these are high‐risk patients who frequently need to proceed urgently to transplant.

TL;DR: BTZ therapy is effective as treatment of MM relapse post allo SCT, it is well tolerated and does not promote GVHD reactions, and the response rates would seem to be higher than the responses reported to donor lymphocyte infusions in this setting.

TL;DR: A patient with maturation arrest of erythropoiesis at the basophilic normoblast stage who had a response to an eight-day course of anti-thymocyte globulin with a return of normal erythroblasts is described.